Skip to main content
. 2011 Dec 7;95(2):297–308. doi: 10.3945/ajcn.111.024927

FIGURE 3.

FIGURE 3.

Percentages (and 95% CIs) of subjects achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss from baseline to week 108 (ITT-LOCF). Standardized lifestyle intervention was used across all treatment groups. *P < 0.0001 compared with placebo; P = 0.0072 compared with placebo. ITT, intent-to-treat; LOCF, last observation carried forward; PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg phentermine/92 mg controlled-release topiramate.